Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-16
2007-10-16
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S374000, C514S326000, C514S256000, C514S255050, C514S340000, C548S236000, C548S209000, C544S137000, C544S333000, C544S405000, C546S271400
Reexamination Certificate
active
10477405
ABSTRACT:
The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.
REFERENCES:
patent: 5089514 (1992-02-01), Hulin
patent: 5232945 (1993-08-01), Hulin
patent: 5306726 (1994-04-01), Hulin
patent: 5902726 (1999-05-01), Kliewer et al.
patent: 5994554 (1999-11-01), Kliewer et al.
patent: 6982278 (2006-01-01), Brooks et al.
patent: 0 930 229 (1999-07-01), None
patent: 1 216 980 (2002-06-01), None
patent: 2 359 082 (2001-08-01), None
patent: WO97 28115 (1997-08-01), None
patent: WO97 31907 (1997-09-01), None
patent: WO99 46232 (1999-09-01), None
patent: WO 01 00566 (2001-01-01), None
patent: WO 01 16120 (2001-03-01), None
patent: WO 02 16332 (2002-02-01), None
patent: WO 02 18355 (2002-03-01), None
patent: WO 02 100813 (2002-12-01), None
Obach R. S., Drug-drug interactions: An important negative attribute in drugs, Drugs of Today, 39(5), 301-38, (2003).
Sarges, R., et al.: “Glucose Transport-Enhancing and Hypoglycemic Activity of 2-Methyl-2-Phenoxy-3-Phenylpropanoic Acids”; Journal of Medicinal Chemistry, vol. 39, No. 24, Nov. 22, 1996, pp. 4783-4803.
Cobb, J. E., et al.: “N-(2-Benzoylphenyl)-L-Tyrosine PPARGamma Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent”; Journal of Medicinal Chemistry, vol. 41, No. 25, Dec. 3, 1998, pp. 5055-5069.
Bright, S.W., et. al.: “Competitive Particle Concentration Fluorescence Immunoassays for Measuring Anti-Diabetic Drug Levels in Mouse Plasma”; Journal of Immunological Methods, vol. 207, No. 1, Aug. 22, 1997, pp. 23-31.
Brooks, D., et al.: “Design and Synthesis of 2-methyl-2-{4-'2-'5-methyl-2-aryloxazol-4-yl)ethoxylphenoxy}propionic acids: A New Class of Dual PPARAlpha/Gamma Agonists”; Journal of Medicinal Chemistry, vol. 44, No. 13, Jun. 21, 2001, pp. 2061-2064.
Shinkai, H. et al.: “Isoxazolidine-3,5-dione and Noncyclic 1,3-dicarbonyl Compounds as Hypoglycemic Agents”; Journal of Medicinal Chemistry, vol. 41, No. 11, May 21, 1998, pp. 1927-1933.
Murugesan, N., et al.: “Biphenylsulfonamide Endothelin Receptor Antogonists 2. Discovery of 4′-oxazoly-lbiphenylsulfonamides as a New Class of Poent, Highly Selective ET(A)Antagonists”; Journal of Medicinal Chemistry, vol. 43, No. 16, Aug. 10, 2000, pp. 3111-3117.
Malamas, M.S., et al.: “Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors fo 5-Lipoxygenase”; Journal of Medicinal Chemistry, vol. 39, No. 1, Jan. 5, 1996, pp. 237-245.
Merguro, K., et al.: “Studies on Antidiabetic Agents. VII. Synthesis and Hypoglycemic Activity fo 4-Oxazoleacetic Acid Derivatives”; Chemical & Pharmaceutical Bulletin, vol. 34, No. 7, 1986, pp. 2840-2851.
Gossett Lynn Stacy
Green Jonathan Edward
Henry James Robert
Jones Winton Dennis
Matthews Donald Paul
Anderson Rebecca
Eli Lilly and Company
Jang Soonhee
Vorndran-Jones MaCharri
LandOfFree
Modulators of peroxisome proliferator activated receptors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of peroxisome proliferator activated receptors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of peroxisome proliferator activated receptors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3824191